The findings, by lead author Peggy Porter, M.D., of Fred Hutchinson Cancer Research Center, in collaboration with colleagues from nine other institutions, appear in the Dec. 6 issue of the Journal of the National Cancer Institute. More than a decade ago, Porter and colleagues at the Hutchinson Center identified p27, a protein that prevents cells from dividing. Since then, several population-based and clinical studies at the Hutchinson Center and elsewhere have indicated that abnormally low levels of this protein in tumor cells are associated with poor prognosis for breast and other cancers.
This link suggests that p27 may be a useful clinical biomarker, or predictor, of breast-cancer survival. However, such attempts to determine the prognostic value of p27 have been limited by the fact that the women studied have not received uniform treatment, so it has been unclear whether certain treatments may impact the strength of p27 as a predictor of outcome.
Now, for the first time, researchers have confirmed the link between low p27 expression and decreased breast-cancer survival in a large randomized, controlled clinical trial of two standard chemotherapy drugs.
"Being able to look at the impact of p27 on breast-cancer outcome in a clinical setting in which all the women were treated similarly allows us to tease out the relationship between the expression of this protein and breast-cancer mortality. Until now, we haven't been able to look at this," said Porter, a member of the Hutchinson Center's Human Biology and Public Health Sciences divisions.
The researchers found that low p27 expression is associated with poor breast-cancer prognosis, particularly among women with hormone-receptor-positive tumors, which depend on the hormones estrogen and progesterone to grow. Specifically, they found the five-year survival was 91 percent in women whose tumors had high p27 expression, as compared to a survival rate of 85 percent in women whose tumors exhibited low p27 expression. The researchers found no association between p27 expression and decreased survival among women with hormone-receptor-negative tumors.
The multicenter study involved more than 3,000 women nationwide (median age 47) with newly diagnosed moderate-risk, primary breast cancer who underwent treatment with doxorubicin and cyclophosphamide. The trial was designed to assess the effectiveness of giving the drugs together (concurrently) or one after the other (sequentially). The study was conducted through the Southwest Oncology Group, one of the largest cancer clinical trials cooperative research efforts in the United States.
Tissue samples for the study were provided by several SWOG clinical-trial groups (the Eastern Cooperative Group, North Central Cancer Treatment Group, and Cancer and Leukemia Group B). "The collaboration among these groups enabled us to gather enough data to produce statistically significant results," said Porter, whose Hutchinson Center team analyzed more than 2,000 breast-tumor samples for p27 expression. The specimens were analyzed via tissue microarray, a relatively new technique that mimics high-throughput methods originally developed for large-scale genetic analysis.
Using this method, many tumor samples can be analyzed for protein expression at once.
While the findings suggest that p27 may be a useful clinical tool for predicting breast-cancer mortality, more work needs to be done before it sees widespread use, Porter said.
"I think p27 has clinical potential, but we still need to define which patient populations are going to benefit most. Right now it looks like it may be most useful for predicting outcome and tailoring treatment in women whose tumors are hormone-receptor positive," Porter said.
Kristen Lidke Woodward | EurekAlert!
Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel
Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences